• Topas and Lilly sign deal to focus on immune tolerance pharmaceutical-technology
    August 24, 2017
    German biotechnology company Topas Therapeutics has signed a multi-year agreement with Eli Lilly and Company to jointly work on antigen-specific tolerance induction, with an initial focus on external antigens thought to induce inflammation and / or autoim
  • Lilly pens deal for Evotec spinout’s immune tolerance drugs fiercebiotech
    August 23, 2017
    Eli Lilly's headquartersTopas spun out of Evotec last year, picking up €14 million ($16 million) from its parent company and other investors along the way.
PharmaSources Customer Service